Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.96

-0.29 (-0.37%)

, JNJ

Johnson & Johnson

$118.13

0.86 (0.73%)

14:40
10/02/16
10/02
14:40
10/02/16
14:40

Novartis reports multiple data sets on psoriasis therapy Cosentyx

Novartis (NVS) announced new data showing Cosentyx, or secukinumab delivers efficacy in patients with moderate to severe plaque psoriasis out to four years of treatment. These data come from the extension study of the Phase III SCULPTURE trial. Results were presented for the first time at the European Academy of Dermatology and Venereology Congress. SCULPTURE extension patients received the same blinded maintenance treatment regimen and dose up to the end of Year 3. In the fourth year, the study became open label. All results presented are for the Cosentyx 300 mg every 4 weeks group. Almost clear skin -- PASI 90 -- was achieved by 68.5% of patients at Year 1 and 61.9% of patients at Year 3, and was maintained at Year 4 in 66.4% of patients. Completely clear skin -- PASI 100 -- was achieved by 43.8% of patients at Year 1 and 41.7% of patients at Year 3, and was maintained at Year 4 in 43.5% of patients. The average improvement of psoriasis as measured by the PASI score was maintained at over 90% after 4 years of treatment. The historic standard goal of treatment, PASI 75 skin clearance, was achieved by 88.9% of patients at Year 1 and 78.4% of patients at Year 3, and was maintained by 88.5% of patients at Year 4. The most common adverse events at Year 4 were nasopharyngitis -- 12.1% -- and upper respiratory tract infection -- 3.5% -- and were similar to those observed at Year 1. Also presented at EADV were results from the GESTURE study demonstrating the strength of Cosentyx versus placebo in patients with moderate to severe palmoplantar plaque psoriasis. At Week 16, about 40% of patients achieved clear or almost clear palms and soles with Cosentyx 300 mg every 4 weeks, which continued to improve with approximately 60% of patients achieving clear or almost clear palms and soles at Week 80. AEs were reported in 47 of the 69 patients receiving Cosentyx and 27 of the 68 patients receiving placebo at Week 80. Additional data presented at EADV from a study in moderate to severe scalp psoriasis showed Cosentyx demonstrated superior efficacy compared to placebo. In the study, Psoriasis Scalp Severity Index 90 responses were achieved by a significantly greater percentage of patients receiving Cosentyx 300 mg -- 52.9% -- than placebo -- 2.0% -- at Week 12. No serious AEs were reported with Cosentyx. The company noted that newly published data also show Cosentyx delivers superior, long-lasting skin clearance versus Stelara, or ustekinumab, for up to 1 year in patients with moderate-to-severe psoriasis: 76% for Cosentyx vs. 61% for Johnson & Johnson's (JNJ) Stelara at 52 weeks.

NVS

Novartis

$78.96

-0.29 (-0.37%)

JNJ

Johnson & Johnson

$118.13

0.86 (0.73%)

  • 07

    Oct

  • 18

    Oct

  • 06

    Nov

NVS Novartis
$78.96

-0.29 (-0.37%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.
JNJ Johnson & Johnson
$118.13

0.86 (0.73%)

08/18/16
UBSW
08/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson remains a top large cap pick, says UBS
UBS analyst Matt Miksic said Johnson & Johnson remains a top large cap diversified pick for the year. The analyst said yesterday's court ruling that invalidated the company's Remicade patent was expected and could delay the Q4 biosimilar launch but its robust pharma pipeline remains under-appreciated and should make up the difference. He said he continues to see further clarity regarding potential U.S. biosimilar competition for Remicade as positive for the stock. Miksic reiterated his Buy rating and $137 price target on Johnson & Johnson shares.
08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.

TODAY'S FREE FLY STORIES

RAD

Rite Aid

$3.93

0.19 (5.08%)

, WBA

Walgreens Boots Alliance

$77.09

-0.17 (-0.22%)

20:25
06/28/17
06/28
20:25
06/28/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

RAD

Rite Aid

$3.93

0.19 (5.08%)

WBA

Walgreens Boots Alliance

$77.09

-0.17 (-0.22%)

MKC

McCormick

$98.95

0.42 (0.43%)

LNN

Lindsay

$88.04

1.44 (1.66%)

GBX

Greenbrier

$50.00

0.55 (1.11%)

CAG

Conagra Brands

$37.37

0.37 (1.00%)

STZ

Constellation Brands

$183.68

1.4 (0.77%)

AYI

Acuity Brands

$179.73

4.4 (2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 07

    Jul

FUL

H.B. Fuller

$53.67

1.59 (3.05%)

19:53
06/28/17
06/28
19:53
06/28/17
19:53
Earnings
H.B. Fuller narrows FY17 adjusted EPS to $2.57-$2.67 from $2.57-$2.77 »

EPS consensus $2.66.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

FUL

H.B. Fuller

$53.67

1.59 (3.05%)

19:51
06/28/17
06/28
19:51
06/28/17
19:51
Earnings
H.B. Fuller reports Q2 adjusted EPS 62c, consensus 67c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

NERV

Minerva

$7.95

-0.65 (-7.56%)

19:46
06/28/17
06/28
19:46
06/28/17
19:46
Syndicate
Minerva 5M share Secondary priced at $7.75 »

Citi and Jefferies acted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

GOV

Government Properties

$19.33

-2.565 (-11.72%)

19:45
06/28/17
06/28
19:45
06/28/17
19:45
Syndicate
Government Properties 25M share Secondary priced at $18.50 »

Citi, BofA/Merrill,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

APRN

Blue Apron

19:41
06/28/17
06/28
19:41
06/28/17
19:41
Syndicate
Blue Apron 30M share IPO priced at $10.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

SO

Southern Company

$49.15

-0.25 (-0.51%)

, TOSBF

Toshiba, also use TOSYY

$2.57

-0.03 (-1.15%)

19:29
06/28/17
06/28
19:29
06/28/17
19:29
Hot Stocks
Georgia Power, Southern Nuclear to assume Vogtle project management by late July »

Georgia Power (SO) and…

SO

Southern Company

$49.15

-0.25 (-0.51%)

TOSBF

Toshiba, also use TOSYY

$2.57

-0.03 (-1.15%)

TOSYY

Toshiba, also use TOSBF

$15.28

-0.39 (-2.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$199.62

0.73 (0.37%)

, BDRBF

Bombardier

$1.87

0.039 (2.13%)

19:29
06/28/17
06/28
19:29
06/28/17
19:29
Periodicals
Boeing requests delay in ruling on Bombardier complaint, Reuters says »

Boeing (BA) has requested…

BA

Boeing

$199.62

0.73 (0.37%)

BDRBF

Bombardier

$1.87

0.039 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BAC

Bank of America

$23.88

0.61 (2.62%)

, BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

19:22
06/28/17
06/28
19:22
06/28/17
19:22
Periodicals
Berkshire may swap Bank of America preferred shares after CCAR news, WSJ says »

After Bank of America…

BAC

Bank of America

$23.88

0.61 (2.62%)

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WATT

Energous

$15.39

0.16 (1.05%)

, DLGNF

Dialog Semiconductor

19:01
06/28/17
06/28
19:01
06/28/17
19:01
Hot Stocks
Dialog invests extra $15M in Energous »

Energous (WATT) announced…

WATT

Energous

$15.39

0.16 (1.05%)

DLGNF

Dialog Semiconductor

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$187.92

0.51 (0.27%)

18:59
06/28/17
06/28
18:59
06/28/17
18:59
Periodicals
Anthem to curtail plan offerings in most of Nevada, WSJ reports »

Anthem plans to stop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSN

VeriSign

$93.77

0.97 (1.05%)

18:36
06/28/17
06/28
18:36
06/28/17
18:36
Hot Stocks
VeriSign says renews .net control through 2023 »

VeriSign disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$81.28

0.59 (0.73%)

, DOW

Dow Chemical

$63.25

0.62 (0.99%)

18:34
06/28/17
06/28
18:34
06/28/17
18:34
Hot Stocks
DuPont, Dow Chemical boards reiterate support of merger agreement »

Dow Chemical Company…

DD

DuPont

$81.28

0.59 (0.73%)

DOW

Dow Chemical

$63.25

0.62 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TPX

Tempur Sealy

$50.87

0.07 (0.14%)

18:33
06/28/17
06/28
18:33
06/28/17
18:33
Hot Stocks
Tempur Sealy enters standstill pact with H Partners, board member Nabi »

Tempur Sealy disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALJ

Alon USA Energy

$13.33

0.15 (1.14%)

, DK

Delek US

$26.43

0.25 (0.95%)

18:26
06/28/17
06/28
18:26
06/28/17
18:26
Hot Stocks
Alon USA Energy stockholders approve Delek US merger »

Alon USA Energy (ALJ)…

ALJ

Alon USA Energy

$13.33

0.15 (1.14%)

DK

Delek US

$26.43

0.25 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

ANCUF

Alimentation Couche-Tard

$49.30

0.144 (0.29%)

, CST

CST Brands

18:25
06/28/17
06/28
18:25
06/28/17
18:25
Hot Stocks
Alimentation Couche-Tard confirms closing of CST Brands acquisition »

Alimentation Couche-Tard…

ANCUF

Alimentation Couche-Tard

$49.30

0.144 (0.29%)

CST

CST Brands

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$50.60

0.92 (1.85%)

18:04
06/28/17
06/28
18:04
06/28/17
18:04
Hot Stocks
BNY Mellon announces strategic alliance with One Investment Group »

BNY Mellon and One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

PRGS

Progress Software

$30.82

0.74 (2.46%)

, WOR

Worthington

$47.36

2 (4.41%)

18:03
06/28/17
06/28
18:03
06/28/17
18:03
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

PRGS

Progress Software

$30.82

0.74 (2.46%)

WOR

Worthington

$47.36

2 (4.41%)

GEMP

Gemphire Therapeutics

$12.27

0.43 (3.63%)

NXTD

Nxt-ID

$1.66

0.2505 (17.77%)

KLIC

Kulicke & Soffa

$20.02

0.53 (2.72%)

SRPT

Sarepta

$33.86

0.83 (2.51%)

SPLS

Staples

$9.93

0.77 (8.41%)

FITB

Fifth Third

$25.49

0.4 (1.59%)

DFS

Discover

$61.88

0.81 (1.33%)

STI

SunTrust

$56.09

0.88 (1.59%)

C

Citi

$65.18

0.95 (1.48%)

RF

Regions Financial

$14.09

0.09 (0.64%)

BK

BNY Mellon

$50.60

0.92 (1.85%)

JPM

JPMorgan

$89.82

1.77 (2.01%)

CFG

Citizens Financial

$35.34

0.5 (1.44%)

BAC

Bank of America

$23.88

0.61 (2.62%)

MS

Morgan Stanley

$44.32

0.1 (0.23%)

WFC

Wells Fargo

$54.33

1.17 (2.20%)

PNC

PNC Financial

$123.40

2.28 (1.88%)

ZION

Zions Bancorp

$42.97

0.43 (1.01%)

GS

Goldman Sachs

$223.22

2.94 (1.33%)

AXP

American Express

$83.97

0.89 (1.07%)

USB

U.S. Bancorp

$51.98

0.84 (1.64%)

PIR

Pier 1 Imports

$5.38

0.04 (0.75%)

BLCM

Bellicum Pharmaceuticals

$13.32

0.18 (1.37%)

AKBA

Akebia

$15.50

-0.19 (-1.21%)

DOC

Physicians Realty Trust

$21.60

0.08 (0.37%)

CRZO

Carrizo Oil & Gas

$15.61

-0.47 (-2.92%)

COF

Capital One

$82.98

1.6 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 25

    Jul

  • 26

    Jul

  • 03

    Aug

  • 26

    Sep

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 30

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

VRX

Valeant

$17.15

0.5 (3.00%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Salix confirms FDA accepts NDA for PLENVU »

Valeant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

NTNX

Nutanix

$20.36

1.72 (9.23%)

, GOOG

Alphabet

$940.49

13.16 (1.42%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Nutanix announces strategic alliance with Google Cloud »

Nutanix (NTNX) announced…

NTNX

Nutanix

$20.36

1.72 (9.23%)

GOOG

Alphabet

$940.49

13.16 (1.42%)

GOOGL

Alphabet Class A

$961.01

12.92 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

CE

Celanese

$93.42

0.62 (0.67%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Celanese increases price of Dibutyl Maleate and Dioctyl Maleate in Europe »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$223.22

2.94 (1.33%)

18:00
06/28/17
06/28
18:00
06/28/17
18:00
Hot Stocks
Goldman Sachs: Fed did not object to capital plan »

Goldman Sachs announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 17

    Oct

COLB

Columbia Banking

$39.35

0.49 (1.26%)

17:56
06/28/17
06/28
17:56
06/28/17
17:56
Hot Stocks
Columbia Banking names Hadley Robbins CEO »

Columbia Banking System…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFBK

Northfield Bancorp

$17.36

0.3 (1.76%)

17:55
06/28/17
06/28
17:55
06/28/17
17:55
Hot Stocks
Northfield Bancorp CEO John Alexander to retire, Steven Klein to succeed »

Northfield Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$22.96

0.25 (1.10%)

, AAL

American Airlines

$49.25

0.75 (1.55%)

17:43
06/28/17
06/28
17:43
06/28/17
17:43
Hot Stocks
Homeland Security announces new aviation security measures »

Secretary of Homeland…

JBLU

JetBlue

$22.96

0.25 (1.10%)

AAL

American Airlines

$49.25

0.75 (1.55%)

UAL

United Continental

$76.70

0.7 (0.92%)

DAL

Delta Air Lines

$53.84

1 (1.89%)

LUV

Southwest

$62.01

0.5 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 07

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.